Business Wire

1. Eluciderm, Inc. Announces U.S. FDA Clearance Of IND Application For ELU42 7/8/2025

   Eluciderm, Inc., a clinical-stage pharmaceutical company developing small molecule therapeutics designed to promote healing and regenerative repair of injured tissue, announced today that on June 30, 2025 the company received clearance from the U.S.

2. FF-10832 Granted FDA Orphan Drug Designation For The Treatment Of Biliary Tract Cancer 7/7/2025

   FUJIFILM Pharmaceuticals U.S.A., Inc., drug development center and a leading provider of Contract Development and Manufacturing Organization (CDMO) services for drug delivery system (DDS) technologies, today announced that the U.S.

3. Quiver Bioscience Secures Non-Dilutive Funding To Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities And Advance Powerful AI/ML-Based In Vitro / In Silico Predictor Of CNS Drug Safety 7/1/2025

   Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, today announced receipt of a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

4. Healx And SCI Ventures Join Forces To Uncover Cures For Paralysis With AI-Driven Drug Discovery 7/1/2025

   Healx, a pioneer in AI-powered drug discovery for rare and neglected conditions, has partnered with SCI Ventures - the world’s first specialist venture fund focused on curing paralysis- to accelerate the discovery and development of therapies for spinal cord injury (SCI) using artificial intelligence.

5. Rocket Pharmaceuticals Announces FDA IND Clearance Of RP-A701 For The Treatment Of BAG3-Associated Dilated Cardiomyopathy 6/30/2025

   Rocket Pharmaceuticals, Inc., a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.

6. Enhanced Genomics And The ALBORADA Drug Discovery Institute Partner To Accelerate Alzheimer's Drug Discovery 6/24/2025

   Enhanced Genomics (‘Enhanced’ or ‘the Company’), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced a strategic partnership with The ALBORADA Drug Discovery Institute at the University of Cambridge.

7. Axcelead DDP And Superluminal Announce The Intent To Collaborate On Drug Discovery Targeting Specific Molecular Mechanisms, Continuing A Productive Relationship 6/23/2025

   Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) and Superluminal Medicines, Inc. (Superluminal) announced the intention to collaborate on drug discovery targeting specific molecular mechanisms associated with challenging biological targets.

8. Archeus Technologies Receives FDA Clearance Of Investigational New Drug Application For ART-101 In Development For The Treatment Of Prostate Cancer 6/20/2025

   Archeus Technologies, a company developing radiopharmaceutical therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer.

9. Circle Pharma Receives FDA Orphan Drug Designation For CID-078 For The Treatment Of Small Cell Lung Cancer 6/16/2025

   Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CID-078 for the treatment of small cell lung cancer (SCLC).

10. Fauna Bio Launches Fauna Brain AI Platform To Accelerate Drug Discovery Inspired By Nature's Most Resilient Species 6/16/2025

    Fauna Bio, a biotechnology company harnessing animal genomics to improve human health, today announced the launch of Fauna Brain, a proprietary AI platform designed to accelerate target discovery and streamline early-stage R&D.